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Chez le groupe de patients de l’étude de 1993
on a trouvé une pourcentage semblable de pneu-
monies (28,4%), mais seulement en deux situations
(3%) on a fait le diagnostique de pneumonie par
Pneumocystis carinii (Table II).
Le diagnostique de tuberculose a été établi en
46,3 % des patients et la pathologie non infectieuse
en 20,9 % des malades .
On a détecté une infection liée au VIH en 27,5 %
des patients avaliées.
Nous pensons pouvoir conclure que la patholo-
gie infectieuse est la responsable pour la majorité
des admissions et quant aux numéros de 1993, la
principal différence est un accroissement significatif
des malades infectées par le VIH, qui conduit a
l’élévation de l’incidence de pneumonies opportun-
istes et probablement des cas de tuberculose.
TABLE II
Diagnostiques comparatives entre les études de 1993 et 2002
1993 n= 67 % 2002 n=146 %
Tuberculose 31 46.3% Tuberculose 78 53.4%
Pneumonie 19 28.4% Pneumonie 38 26.0%
     Pneumonie Pn. car.  2   3% Pneumonie Pn. Car. 14  9.6%
Embolies pulmonaires septiques  1 1,5% Embolies pulmonaires septiques   4 2.7%
Empyème  2 2,9% Abcès pulmonaire   1 0.7%
Bronchite aigue   4 2.7%
Bronchectasies   4 2.7%
Bronchiolite   2 1.4%
Pathologie non-infectieuse 14 20.9% Pathologie non-infectieuse 15 10.3%
VIH+ 13/48 27.1% VIH+ 87 71.9%
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Emphysema is defined in anatomic terms as
enlargement of alveoli and destruction of their walls,
causing them to become confluent and to form
grossly oversized air spaces. Emphysema is usually
distinguished from chronic bronchitis, the other form
of chronic obstructive pulmonary disease (COPD).
Expiratory air flow obstruction occurs late in the
course of the disease and is reflected in decrements
of the forced expiratory volume in one se-cond
(FEV1), when this value falls below 30% of the
predicted normal value, the survival rate is
approximately 87% at 1 year, 72% a 2 years and
59% at 3 years1.
Medical therapy may reduce symptoms, slow
disease progression, and improve survival, but it
can do little to restore lung function and does not
halt the slow downhill course of the disease. When
the disease has progressed to a degree that the
patient’s quality of life has become unbearable, the
surgical options of “Lung Volume Reduction Surgery
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(LVRS)” or “Lung Transplantation (LTx)” may be
considered. The major difficulty facing surgeons lies
in appropriate selection of patients for either
procedure.
It is important to differentiate two types of
emphysema, with prognostic implications in the
surgical treatment: the Panacinar emphysema, more
often affects the lower lobes and is usually
encountered in patients with alpha-1 antitrypsin
deficiency. It is the homogeneous type with no
regional or only minor differences in the severity of
emphysema. And Centriacinar emphysema, the
pattern most frequently associated with smoking,
most commonly involves the upper lobes and may
be quite focal; it is the heterogeneous emphysema
where a distinct regional difference in the severity
of emphysema is present; in the heterogeneous
emphysema we find the named “target areas”, they
are the portions of the lung mostly affected for
emphysema, and we have to identify and resect
them during LVRS.2
LVRS has become an accepted procedure for
palliative treatment of diffuse, non bullous
emphysema. Peripheral segmental wedge resections
of the most destroyed areas of the lungs are
performed, in order to decrease hyperinflation and
restore diaphragmatic function.
In the 1950s Brantigan performed wedge
resections of emphysematous lungs, but the 18%
operative mortality prevented against the
procedure3.  In 1991 Wakabayashi rekindled the
interest with the use of the laser by unilateral
thoracoscopy, but he did not get stimulate
colleagues in the same way4.
In 1994 Cooper and his colleagues modernized
Brantigan’s operation by resecting areas of severe
emphysematous change in both lungs through a
median sternotomy5; they proposed that the removal
of diseased and functionless lung may improve the
function of the remaining lung (increasing elastic
recoil pressure, thereby increasing expiratory air
flow rates; decreasing the degree of hyperinflation
resulting in improved diaphragm and chest wall
mechanics; decreasing the inhomogeneity of regional
ventilation and perfusion, resulting in improved
alveolar gas exchange and increasing effectiveness
of ventilation to maintain blood gas levels).
The Russian Demikhov was the first who
performed an experimental lung transplant in dog,
in 1946. Twenty years later Hardy got on with the
first LTx in human being. But newly Cooper and his
colleagues were the responsibles of the current
world wide LTx expansion, with more than 12000
single and bilateral LTx communicated in the last
report of the “International Society for Heart an Lung
Transplantation” on August 20016. Lung transplant
could be the perfect treatment for patients with
severe emphysema, we change and replace the
diseased emphysematous lung for a new healthy
donor lung.
Which are the common aspects to both
procedures?: we should indicate both procedures
only if patients have received a correct and complete
non surgical treatment and their degree of
deterioration is irrecoverable. In the other hand both
procedures carries a risk of mortality that we should
have in mind if we indicate either, for LVRS it varies
from 0% to 20% with on average of about 4.8%;
for LTx the perioperative mortality is similar but
increased during the first year due to infection
principally7. It is assumed that surgeons recognise
that none of both options are to be regarded as
other than palliation; there is not as yet evidence
that survival is affected by any surgical procedure,
however a recent publication from Meyers and
colleagues favoring survival in LVRS’s patients
versus medical therapy (72% versus 41% at 4
years)8.
We think the most important for indicating LVRS
is the assessment of the hyperinflation degree and
recognising preoperatively the target areas. General
recommendations are to performed LVRS for
patients with FEV1<35% of predicted, residual
volume>150% and total lung capaci-ty>120%.
Every patients have to be studied with CT scan and
lung perfusion scan preoperatively.  The functional
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improvement after LVRS can raise 58% of the
preoperative baseline value in terms of FEV1, the
maximum increase is evident at 6 months after
LVRS, but steadly diminishes later, however some
patients retain benefits at 2-3 years at least9.
There are some unanswered questions to regard
LVRS: Anatomic characteristics of emphysema are
important in patient’s selection for the procedure,
patients with a heterogeneous pattern of
emphysematous involvement with upper lobe
predominance have a better outcome than patients
with a homogeneous pattern or lower lobe
predominance, in the last patients the benefits of
the operation persisted only short for them, and
returned to baseline at 1 year in most cases, with
further deterioration after them. LVRS will only be
beneficial if the remaining lung retains sufficient
function to enable the patient to make use of his
mechanical advantages, in this way the only report
of the “National Emphysema Treatment Trial
(NETT)” at the moment, shows that patients with a
FEV1 equal o less than 20% of predicted, and either
a DLCO equal or less than 20% of predicted, or a
uniform pattern of emphysema distribution on the
CT scan had a higher risk of death, during the first
30 days after surgery, and should to be excluded
of the procedure10. Hypercapnia, pulmonary
hypertension, homogeneity of disease, high degree
of parenchimal destruction are considered risk
factors and should avoid the procedure. From the
published reports it appears that the applied
techniques of LVRS are of minor importance for
the overall success, nonetheless the functional
improvement after bilateral resections exceeds that
after unilateral approach, however we can perform
unilateral LVRS if there are unilateral pattern of
emphysema, prior unilateral chest surgery or pleural
symphysis. Another question is for how long the
results of LVRS last. We have information from very
limited series on the results after more than 2 or 3
years. Published results indicate that 3 years after
LVRS the benefits seem not to persist in the majority
of patients, although there is a small number of
patients who show benefit 5 years after the
operation11,12.
Regarding LTx we can establish the transplant´s
window for COPD if patients presents with a
FEVs<25% of predicted, and/or a PaCO2>55 mm
Hg., and/or pulmonary hypertension13. The results
are a dramatic enhancement in lung function and
performance status, with no limitations in 85% of
survivors at 5 years, and a FEV1 nearly 100% of
predicted if complications are rule out. The concerns
in LTx are the lack of available donor lungs with a
waiting time in United States of two years; that is
different in Spain where only 4% of patients have
to wait in list more than 1 year for a suitable donor
lung, and the mean waiting time in list is less than 5
months. This is an important difference between
United States and us at the time to indicate LVRS
or LTx14. Other issue is the develop of chronic
rejection in 50% of patients at 5 years post-
transplant, with a progressive decline in lung function
and finally death. The last problem is the need for
lifelong immunosupression with a con-tinued risk for
infection.
It is important to realise that up to 70% of
emphysema patients inquiring into LVRS will be
rejected for this surgery due to a variety of medical,
physiologic an anatomic reasons. Only a small
number of patients are candidates for the procedure.
However it has been published that approximately
47% of patients with emphysema referred for
evaluation by a lung transplant program were
candidates for both LVRS and LTx procedures15.
The problem is get to separate the common group
of patients to both procedures for indicating the most
beneficial.
Following the criteria by Meyers and Patterson,
indications to both procedures are: emphysema with
destruction and hyperinflation; marked impairment,
with FEV1<35% of predicted; marked restriction
in activities of daily living; failure of maximal medical
treatment to correct symtoms. Conditions favoring
LVRS would be: marked thoracic distension;
heterogeneous disease with apical target areas;
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FEV1>20% of predicted; age between 60 and 70
years. Finally conditions favoring LTx are: diffuse
emphysema; FEV1<20% of predicted; hypercarbia
(PaCO2>55 mm Hg.); pulmonary hipertensión; age
less than 60 years; alpha 1 antitrypsin deficiency16.
Revising bibliografy, we can find some studies
which LVRS and LTx has been used jointly.
Wiser and colleagues describes 15 out of 102
LVRS patients that underwent LTx 19,6 monoths
later, in 53% of them LVRS failed to improve FEV1
and in the remaining 47%, FEV1 improved 31,9%
of predicted value; in responders LTx was able to
be delayed more than in non responders; three
months mortality after LTx was 20%, all deaths in
non responders; they concluded that LTx could be
a dangerous option when LVRS has been
unsuccessful17.
Meyers and colleagues studied 99 patients who
met criteria for LVRS and LTx, firstly every patients
underwent LVRS; in the follow-up the results were
better when they performed upper lobe reduction
surgery with a rate of listing for LTx of 27% and an
increase of 63% in FEV1, versus 63% of listing and
30% increase in FEV1 if they performed lower lobe
reduction surgery; they concluded that LVRS do
not preclude posterior LTx and bridged it for 3,8
years18.
Lastly Karen and colleagues matched 15 LVRS
plus LTx patients against 15 only LTx patients, They
did not find any differences in lung function or sur-
vival, and the results were better for bilateral
LVRS19.
We conclude that at the present there are only
evidences that the most important selection factor
for successful LVRS is the presence of a heteroge-
neous pattern of emphysema predominately in up-
per lobes, consistently we are conservative in its
indications; we only performed it if patients meet
the previous criteria, and in the case that do not
preclude a future LTx. We hope that NETT’s re-
sults could clarify the optimal selection of candi-
dates for LVRS, and to identify those with a great-
er risk for the procedure.
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The prescription of an home ventilator according to different diseases:
from setting to family training
MICHELE VITACCA
Fondazione Salvatore Maugeri IRCCS, Gussago (BS) Italy
In recent years, guidelines have been published
in order to define indications, applications and de-
livering of long-term mechanical ventilation (MV).
Noninvasive positive pressure ventilation (NPPV)
has been increasingly used in the management of
chronic respiratory insufficiency both in restrictive
than in obstructive patients. Side-effects due to the
interface may impact the follow-up of these patients
in 20 to 50 % of cases and account for an impor-
tant problem dealing with discontinuation and lack-
ing of compliance. Nonetheless, selection of pa-
tients, modalities of ventilation, types of ventilators
and their setting, have been claimed to account for
these conflicting results. It is has been described
that only 50% of patients with COPD continued to
use NPPV during prolonged follow-up of appro-
ximately 6 months. In the clinical practice, home
NPPV is prescribed as nasal pressure support ven-
tilation (NPSV), and is set to achieve a decrease in
PaCO2 and an optimal patient’s compliance. We
recently demonstrated that when compared to un-
assisted breathing both settings (at patient’s com-
fort, or the physiological setting) indu-ced a signif-
icant improvement in minute ventilation and in dia-
phragm activity as assessed by the diaphragmatic
pressure-time product (PTP); eva-luation of lung
mechanics and respiratory muscle function may re-
sult in reduction in ineffective ins-piratory efforts.
Home NPPV is often prescribed after in-hospital
practice sessions performed with the commercial
ventilators available at the moment (often a single
one), which may be not necessarily that used by
the patient at home. In our laboratory we under-
took a study to compare the patient-ventilator in-
teraction and patient comfort with different com-
mercial bi-level pressure home ventilators. We con-
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